Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: Use of 99Tc-annexin V, 18F-FDG, and histologic evaluation

Journal of Nuclear Medicine

Volumn 46, Issue 5, 2005, Pages 794-799

  Takei, Toshiki ^a   Kuge, Yuji ^a   Zhao, Songji ^a   Sato, Masayuki ^b   Strauss, H William ^c   Blankenberg, Francis G ^d   Tait, Jonathan F ^e   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

18F FDG; 99mTc annexin V; Apoptosis; Cancer chemotherapy; Molecular imaging

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GLUCOSE; GLUCOSE TRANSPORTER 1; INDIUM 111; LIPOCORTIN 5; TECHNETIUM 99M; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M HYNIC ANNEXIN V;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG UPTAKE; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INOCULATION; LIVER CELL CARCINOMA; LIVER WEIGHT; MALE; METABOLISM; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STATISTICAL ANALYSIS; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECT; LIVER TUMOR; METABOLIC CLEARANCE RATE; PATHOLOGY; PROGNOSIS; SCINTISCANNING; STATISTICS; TISSUE DISTRIBUTION; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; FLUORODEOXYGLUCOSE F18; GLUCOSE; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; STATISTICS; TISSUE DISTRIBUTION;

EID: 20644449276     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
3. Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann NY Acad Sci. 2000;926:204-216.
4. Belhocine T, Steinmetz N, Green A, Rigo P. In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann NY Acad Sci. 2003;1010:525-529.
5. 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. Cancer Biother Radiopharm. 2004;19:205-210.
6. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000;60:5451-5455.
7. 99mTc-annexin V. J Nucl Med. 2003;44:92-97.
8. Blankenberg PG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-6354.
9. 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J Nucl Med. 2004;45:309-312.
10. 99mTc- annexin V uptake and histologic findings in an experimental model. J Nucl Med. 2004;45:2083-2087.
11. Cohade C, Wahl RL. PET scanning and measuring the impact of treatment. Cancer J. 2002;8:119-134.
12. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
13. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
14. 18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30(suppl 1):S97-S105.
15. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28:730-735.
16. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-1555.
17. Haberkorn U, Bellemann ME, Brix G, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med. 2001;28:418-425.
18. Wood BL, Gibson DF, Tail JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow cytometric measurement and clinical associations. Blood. 1996;88:1873-1880.
19. Tait JF, Smith C. Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding. Arch Biochem Biophys. 1991;288:141-144.
20. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinase-annexin V chimeras: construction, expression, and characterization of recombinant proteins. J Biol Chem. 1995;270:21594-21599.
21. 99mTc. Bioconjug Chem. 2000;11:918-925.
22. Zhao S, Kuge Y, Tsukamoto E, et al. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun. 2002;23:545-550.
23. Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med. 1997;38:1215-1221.
24. 99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766-2774.
25. van de Wiele C, Lahorte C, Vermessen H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol. 2003;21:3483-3487.
26. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr. 1997;29:315-330.
27. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res. 2003;23:1149-1154.
28. Moley KH, Mueckler MM. Glucose transport and apoptosis Apoptosis. 2000;5:99-105.
29. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193-204.
30. Raff M. Cell suicide for beginners. Nature. 1998;396:119-122.
31. Thorburn A, Thorbum J, Frankel AE. Induction of apoptosis by tumor cell targeted toxins. Apoptosis. 2004;9:19-25.
32. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest. 1999;104:1655-1661.
33. Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.
34. 99mTc-radiolabeled annexin V. J Nucl Med. 2001;42:309-316.
35. Bacurau RF, O'Toole CE, Newsholme P, Costa Rosa LF. Sub-lethal concentrations of activated complement increase rat lymphocyte glutamine utilization and oxidation while lethal concentrations cause death by a mechanism involving ATP depletion. Cell Biochem Funct. 2002;20:183-190.
36. 18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688.
37. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metestatic germ cell tumor. J Nucl Med. 1998;39:815-822.
38. Medina RA, Owen GI. Glucose transporters expression, regulation and cancer. Biol Res. 2002;35:9-26.
39. Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani H. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer. 2003;107:177-182.
40. 13C magnetic resonance spectroscopy. Eppendorf electrode, and redox scanning. Cancer Res. 2003;63:8813-8820.